Photo from Memorial Sloan Kettering Radiation Oncology/X
Jun 7, 2024, 20:40
Secondary analysis of a prospective, phase II RCT for metastatic HNSCC – Memorial Sloan Kettering Radiation Oncology
Memorial Sloan Kettering Radiation Oncology shared on X:
“New from Drs James Janopaul-Naylor and Sean McBride:.
This secondary analysis of a prospective, phase II RCT for metastatic HNSCC (nivolumab +/− SBRT) found no significant impacts on efficacy and toxicity of treatment time-of-day/circadian rhythm.”.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14